-
Je něco špatně v tomto záznamu ?
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
H. Ludwig, W. Pönisch, S. Knop, A. Egle, A. Hinke, M. Schreder, D. Lechner, R. Hajek, E. Gunsilius, A. Petzer, K. Weisel, D. Niederwieser, H. Einsele, W. Willenbacher, H. Rumpold, L. Pour, T. Jelinek, KJ. Krenosz, A. Meckl, S. Nolte, T....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- dexamethason terapeutické užití MeSH
- glycin analogy a deriváty MeSH
- kvalita života * MeSH
- lidé MeSH
- mnohočetný myelom * farmakoterapie MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- sloučeniny boru MeSH
- thalidomid terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.
CCRC Cancer Clinical Research Consulting Düsseldorf Germany
Department of Hematology University of Leipzig Leipzig Germany
Department of Internal Medicine 1 Ordensklinikum Linz Barmherzige Schwestern Linz Austria
Department of Internal Medicine 3 Kepler Universitaetsklinikum GmbH Med Campus 3 Linz Austria
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Department of Medicine 1 Center for Oncology and Hematology Wilhelminen Hospital Vienna Austria
Fakultní Nemocnice Ostrava Ostrava Czech Republic
Medical Department Division of Psychosomatic Medicine Charité Universitätsmedizin Berlin Germany
Oncotyrol Center for Personalized Cancer Medicine Innsbruck Austria
University Medical Center of Hamburg Eppendorf Hamburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020785
- 003
- CZ-PrNML
- 005
- 20210830102430.0
- 007
- ta
- 008
- 210728s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2019.1666381 $2 doi
- 035 __
- $a (PubMed)31556753
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ludwig, Heinz $u Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
- 245 10
- $a Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population / $c H. Ludwig, W. Pönisch, S. Knop, A. Egle, A. Hinke, M. Schreder, D. Lechner, R. Hajek, E. Gunsilius, A. Petzer, K. Weisel, D. Niederwieser, H. Einsele, W. Willenbacher, H. Rumpold, L. Pour, T. Jelinek, KJ. Krenosz, A. Meckl, S. Nolte, T. Melchardt, R. Greil, N. Zojer
- 520 9_
- $a This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (≥10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a sloučeniny boru $7 D001896
- 650 _2
- $a dexamethason $x terapeutické užití $7 D003907
- 650 _2
- $a glycin $x analogy a deriváty $7 D005998
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x farmakoterapie $7 D009101
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a thalidomid $x terapeutické užití $7 D013792
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pönisch, Wolfram $u Department of Hematology, University of Leipzig, Leipzig, Germany
- 700 1_
- $a Knop, Stefan $u Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany
- 700 1_
- $a Egle, Alexander $u Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria
- 700 1_
- $a Hinke, Axel $u CCRC Cancer Clinical Research Consulting, Düsseldorf, Germany
- 700 1_
- $a Schreder, Martin $u Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
- 700 1_
- $a Lechner, Daniel $u Department of Medicine I, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
- 700 1_
- $a Hajek, Roman $u Fakultní Nemocnice Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Gunsilius, Eberhard $u Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Petzer, Andreas $u Department of Internal Medicine I, Ordensklinikum Linz - Barmherzige Schwestern, Linz, Austria
- 700 1_
- $a Weisel, Katja $u University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Niederwieser, Dietger $u Department of Hematology, University of Leipzig, Leipzig, Germany
- 700 1_
- $a Einsele, Hermann $u Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany
- 700 1_
- $a Willenbacher, Wolfgang $u Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria $u Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria
- 700 1_
- $a Rumpold, Holger $u Department of Oncology, Hematology and Gastroenterology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
- 700 1_
- $a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Jelinek, Tomas $u Fakultní Nemocnice Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Krenosz, Karl Jochen $u Department of Internal Medicine 3, Kepler Universitaetsklinikum GmbH, Med. Campus III, Linz, Austria
- 700 1_
- $a Meckl, Angela $u Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
- 700 1_
- $a Nolte, Sandra $u Medical Department, Division of Psychosomatic Medicine, Charité- Universitätsmedizin, Berlin, Germany
- 700 1_
- $a Melchardt, Thomas $u Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria
- 700 1_
- $a Greil, Richard $u Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria
- 700 1_
- $a Zojer, Niklas $u Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 61, č. 2 (2020), s. 377-386
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31556753 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102430 $b ABA008
- 999 __
- $a ok $b bmc $g 1691378 $s 1141231
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 61 $c 2 $d 377-386 $e 20190926 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20210728
